Journals Books 2687-5527
Latest Issue Archive Future Issues About Us
Conference Proceedings

SETSCI - Volume 4 (6) (2019)
ISAS WINTER-2019 (ENS) - 4th International Symposium on Innovative Approaches in Engineering and Natural Sciences, Samsun, Turkey, Nov 22, 2019

Alzheimer's and Huntington as Neurodegenerative Diseases
Tuğçe Karaduman1, Habibe Kutuk2*
1Aksaray University, Aksaray, Turkey
2Aksaray University, Aksaray, Turkey
* Corresponding author:
Published Date: 2019-12-22   |   Page (s): 101-103   |    223     6

ABSTRACT Neurodegenerative diseases (NDD) are a group of diseases characterized by progressive loss of neuron function and structural deterioration. This may be due to damage at birth, as well as by the effect of genetic factors and aging, or as a combination of these. Of these diseases, the more common Alzheimer's disease (AD) generally presents at an advanced age, while Huntington disease (HD) tends to occur at an early age. AD is the most common cause of dementia in the elderly. AD is the most common cause of dementia in the elderly, is a progressive neurodegenerative disease that causes loss of cognitive function and ultimately death. The pathology of AD is mainly composed of senile plaques and neurofibrillary tangles (NFT). HD, one of the neurodegenerative diseases of the central nervous system, is a trinucleotide repeat disorder. HD is characterized by involuntary movements called Korea, memory loss, impaired motor coordination, and accompanying psychiatric symptoms. In this study, the most common neurodegenerative disease (Alzheimer's and Huntington disease) will be discussed and experimental models designed to investigate the pathogenesis, diagnosis and treatment options of neurodegenerative diseases will be discussed.  
KEYWORDS Neurodegenerative diseases, Alzheimer’s, Huntington, experimental models
REFERENCES [1] Shamim IA. Neurodegenerative Diseases. New York: Springer; 2012.
[2] Avila J, Lucas J, Hernandes F. Animal Models for Neurodegenerative Disease. Cambridge: The Royal Society of Chemistry; 2011.
[3] Hardiman O, Doherty CP, Elamin M, Bede P. Neurodegenerative Disorders. Switzerland: Springer International Publishing; 2016.
[4] Cankurtaran M, Arıo¤ul S. Alzheimer hastalı¤ı ve demans tedavisinde yenilikler. Türkiye Tıp Dergisi 2002; 9:128-36.
[5] Perl DP. Neuropathology of Alzheimer's Disease. Mt Sinai J Med 2010;77:32-42
[6] Şahin Ş. Deneysel Alzheimer Hastalı¤ı Modelleri. Turkiye Klinikleri Journal of Neurology Special Topics 2012;5:102-6.
[7] Puzzo D, Gulisano W, Palmeri A, Arancio O. Rodent models for Alzheimer's disease drug discovery. Expert Opin Drug Discov 2015;10:703-11.
[8] Chesselet MF, Carmichael ST. Animal models of neurological disorders. Neurotherapeutics 2012;9:241-4.
[9] Bajo R, Pusil S, López ME, Canuet L, Pereda E, Osipova D, et al. Scopolamine effects on functional brain connectivity: a pharmacological model of Alzheimer's disease. Sci Rep 2015;5:9748.
[10] McGowan E, Eriksen J, Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006;22:281-9.
[11] Ersoy N, Başak AN. Molecular Biology of Huntington's Disease. Turk J Neurol 2005;11:27-44.
[12] Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nature Reviews. Neuroscience 2013;14:708–21.
[13] Li JY, Popovic N, Brundin P. The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx 2005;2:447–64.

SET Technology - Turkey

eISSN  : 2687-5527    

E-mail :
+90 533 2245325

Tokat Technology Development Zone Gaziosmanpaşa University Taşlıçiftlik Campus, 60240 TOKAT-TURKEY
©2018 SET Technology